Markets:

Overview

News

Currencies

International

Treasuries

Heron Therapeutics, Inc. - Common Stock (NQ:HRTX)

0.9619 -0.0581 (-5.70%)

Streaming Delayed Price Updated: 1:16 PM EST, Mar 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Heron Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 12, 2023

Gainers GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial results for its fiscal fourth quarter after the market close on May 16,...

Via Benzinga

Dow Turns Lower; Getaround Shares Jump ↗

May 12, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones turning lower on Friday. The Dow traded down 0.25% to 33,226.13 while the NASDAQ fell 0.45% to 12,271.22. The S&P 500, also fell,...

Via Benzinga

Analyst Expectations for Heron Therapeutics's Future ↗

May 12, 2023

Via Benzinga

Recap: Heron Therapeutics Q1 Earnings ↗

May 11, 2023

Via Benzinga

Earnings Preview: Heron Therapeutics ↗

May 10, 2023

Via Benzinga

Why Heron Therapeutics Stock Has Been on Fire This Week ↗

April 06, 2023

Wall Street is cheering a change in leadership at the company.

Via The Motley Fool

Why Shares of Heron Therapeutics Jumped Thursday ↗

April 06, 2023

The stock has been rising since the company appointed a new CEO.

Via The Motley Fool

These 2 Growth Stocks Might Be Incredibly Undervalued Right Now ↗

April 20, 2023

These two biopharma stocks could be poised for a major growth spurt.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 06, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

April 05, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders need to know about this morning!

Via InvestorPlace

Heron Therapeutics's Earnings Outlook ↗

March 22, 2023

Via Benzinga

Analysts Cut Price Targets As Heron Therapeutics' Zynrelef Disappoints In Q3 ↗

November 09, 2022

Via Benzinga

FDA Approves Heron Therapeutics' Post-Op Nausea Treatment ↗

September 19, 2022

Via Benzinga

Heron Shares Jump After Equity Financing, Q2 Earnings ↗

August 09, 2022

Via Benzinga

Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 24, 2023

Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50.

Via Benzinga

Why Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

March 24, 2023

Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 58.7% to $0.2250 in pre-market trading after gaining more than 17% on Thursday. Bird announced plans to expand across Greater Toronto area this...

Via Benzinga

Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 06, 2023

Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54.

Via Benzinga

Earnings Scheduled For March 23, 2023 ↗

March 23, 2023

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.

Via Benzinga

Heron Therapeutics Files For Expanded Use Of Zynrelef In Soft Tissue, Orthopedic Surgical Procedures ↗

December 29, 2022

Via Benzinga

7 Penny Stocks to Buy for 10-Bagger Returns ↗

November 15, 2022

These penny stocks provide the potential for multibagger returns for those seeking less-speculative stocks with a decent growth outlook.

Via InvestorPlace

Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

February 22, 2023

Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous...

Via Benzinga

Earnings Outlook For Heron Therapeutics ↗

November 07, 2022

Heron Therapeutics (NASDAQ:HRTX) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Heron...

Via Benzinga

Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends ↗

November 04, 2022

Although it’s not great energy to be a “hater,” the reality is that some stocks to sell must be exited from your portfolio.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 07, 2022

Gainers

Via Benzinga

4 No-Brainer Penny Stocks to Buy if You Have Money to Invest ↗

September 26, 2022

These are some of the top undervalued stocks with impending growth catalysts

Via InvestorPlace

7 Unknown Biotech Stocks That Could Rocket in 2023 ↗

September 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Via InvestorPlace

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗

August 10, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

Via Benzinga

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session ↗

August 09, 2022

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.